Cantor Fitzgerald reaffirmed their buy rating on shares of Radius Health, Inc. (NASDAQ:RDUS) in a research note issued to investors on Friday, November 3rd. The firm currently has a $58.00 target price on the biopharmaceutical company’s stock.
Other research analysts also recently issued research reports about the company. Canaccord Genuity set a $85.00 price target on Radius Health and gave the company a buy rating in a report on Monday, July 17th. BidaskClub downgraded Radius Health from a hold rating to a sell rating in a report on Friday, August 11th. Jefferies Group LLC reissued a hold rating and issued a $38.00 price target (up previously from $34.00) on shares of Radius Health in a report on Wednesday, August 9th. Zacks Investment Research raised Radius Health from a sell rating to a hold rating in a report on Tuesday, August 8th. Finally, Maxim Group reaffirmed a positive rating on shares of Radius Health in a report on Friday, September 29th. They noted that the move was a valuation call. Two investment analysts have rated the stock with a sell rating, four have given a hold rating and five have issued a buy rating to the stock. The company currently has an average rating of Hold and an average price target of $51.00.
Shares of Radius Health (RDUS) opened at $27.71 on Friday. The company has a debt-to-equity ratio of 0.53, a quick ratio of 12.79 and a current ratio of 12.87. Radius Health has a 12 month low of $27.16 and a 12 month high of $55.97.
Radius Health (NASDAQ:RDUS) last posted its earnings results on Thursday, November 2nd. The biopharmaceutical company reported ($1.31) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.28) by ($0.03). The firm had revenue of $13.50 million during the quarter, compared to analyst estimates of $6.90 million. During the same period in the prior year, the business posted ($1.07) EPS. sell-side analysts predict that Radius Health will post -5.4 EPS for the current fiscal year.
In other Radius Health news, VP Brent Hatzis-Schoch bought 1,778 shares of the stock in a transaction that occurred on Friday, November 10th. The shares were purchased at an average cost of $28.09 per share, for a total transaction of $49,944.02. Following the transaction, the vice president now directly owns 2,278 shares in the company, valued at $63,989.02. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Jesper Hoiland purchased 6,800 shares of the stock in a transaction dated Tuesday, November 7th. The shares were purchased at an average price of $29.04 per share, for a total transaction of $197,472.00. Following the completion of the transaction, the insider now owns 12,900 shares in the company, valued at approximately $374,616. The disclosure for this purchase can be found here. Over the last 90 days, insiders purchased 427,678 shares of company stock worth $14,430,298. 15.00% of the stock is owned by insiders.
Hedge funds have recently modified their holdings of the company. Sei Investments Co. increased its position in shares of Radius Health by 27.7% during the 2nd quarter. Sei Investments Co. now owns 3,180 shares of the biopharmaceutical company’s stock valued at $144,000 after purchasing an additional 690 shares during the period. Ameritas Investment Partners Inc. increased its position in shares of Radius Health by 19.9% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 3,266 shares of the biopharmaceutical company’s stock valued at $148,000 after purchasing an additional 541 shares during the period. Advisor Group Inc. increased its position in shares of Radius Health by 267.2% during the 2nd quarter. Advisor Group Inc. now owns 3,969 shares of the biopharmaceutical company’s stock valued at $180,000 after purchasing an additional 2,888 shares during the period. Blair William & Co. IL acquired a new position in shares of Radius Health during the 2nd quarter valued at $205,000. Finally, Amalgamated Bank acquired a new position in shares of Radius Health during the 2nd quarter valued at $211,000.
About Radius Health
Radius Health, Inc is a biopharmaceutical company. The Company is focused on the developing therapeutics in the areas of osteoporosis, oncology and endocrine diseases. The Company’s lead investigational product candidate, TYMLOS (abaloparatide-SC) injection is developed for the treatment of postmenopausal women with osteoporosis at high risk for fracture.
Receive News & Ratings for Radius Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Radius Health Inc. and related companies with MarketBeat.com's FREE daily email newsletter.